Abstract
Understanding cancer progression requires modeling how gene expression evolves over time. However, clinical datasets often suffer from censored survival data and irregular temporal snapshots. We present SurvODE, a framework that combines Variational Autoencoders (VAEs), Neural Ordinary Differential Equations (Neural ODEs), and Cox Proportional Hazards (Cox-PH) models. By estimating pseudo-survival times for censored observations, SurvODE enables the continuous modeling of gene expression distributions, allowing for the extrapolation of biological states to early disease stages where data is typically unavailable.
Introduction
Cancer research increasingly relies on large-scale genomic datasets like The Cancer Genome Atlas (TCGA). Despite the wealth of data, two primary obstacles hinder the reconstruction of disease progression: censored data and irregular population snapshots. Censoring occurs when a patient's exact survival time is unknown (e.g., they are still alive at the study's end), providing only a lower bound on survival. Furthermore, genomic profiles are usually single-point observations across a population rather than continuous time-series for individuals. Existing methods often fail to capture the underlying distribution of gene expressions over time, limiting their utility for early cancer detection—the "holy grail" of oncology.
The SurvODE Framework
SurvODE addresses these challenges through a modular architecture designed to handle high-dimensional, noisy, and censored biological data. The framework operates in two distinct phases.
The core components include:
- Variational Autoencoder (VAE): Compresses high-dimensional gene expression data into a low-dimensional latent space, mitigating noise and capturing essential biological features.
- Neural ODE Module: Models the evolution of latent representations as a continuous-time process. Unlike discrete neural networks, Neural ODEs can be queried at any arbitrary time point, making them ideal for irregular clinical data.
- Cox Proportional Hazards (Cox-PH) Module: Bridges the gap between survival analysis and generative modeling. It estimates "pseudo-survival times" for censored patients, allowing the model to utilize the entire dataset for training.
Experimental Results
The model was evaluated on eight cancer types from TCGA, focusing on the most time-relevant genes. A key test involved "extrapolation": predicting gene distributions for the 20% of patients with the longest survival times (representing early-stage cancer) which were withheld during training.
As shown in the results, SurvODE significantly outperformed standard VAEs and Conditional VAEs (CVAEs) across nearly all cancer types, including Bladder (BLCA), Breast (BRCA), and Glioma (GBMLGG). Beyond quantitative metrics, the model demonstrated biological relevance. In Glioma, SurvODE identified 16 potential early-stage biomarkers, such as TAGLN2, which has been independently linked to tumorigenesis in existing literature.
Discussion and Conclusion
SurvODE represents a significant step forward in modeling the "arrow of time" in cancer progression. By predicting distributions rather than just mean values, it captures the increasing variance often associated with disease development. While the model currently relies on the proportional hazards assumption of the Cox model, its ability to extrapolate to unobserved early stages offers a powerful tool for biomarker discovery. Future work may extend this framework to model complex gene-gene interactions, further refining our understanding of early-stage oncogenesis.
Summary updated